GlobeNewswire

Nuritas Brings Industry Pharma Thought Leaders Together to Accelerate Drug Discovery with AI

Share

DUBLIN, Ireland, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nuritas, a biotechnology company discovering life-changing drugs through the power of artificial intelligence (AI) based peptide discovery, today announced it will be presenting to and subsequently hosting an interactive workshop with global pharmaceutical industry leaders at the annual AI in Pharma Summit 2018 on Tuesday, October 9th, 2018 in Boston, MA.

“Artificial intelligence is an emerging technology with great promise in drug discovery,” said Emmet Browne, chief executive officer of Nuritas. “At Nuritas, we harness the power of AI to rapidly and efficiently discover peptide-based therapies for the world’s growing healthcare needs, with unmatched success rates across a broad range of disease areas. However, much work remains in understanding and maximizing the impact of this emerging technology.”

The workshop will explore how AI can be utilized to discover the next generation of therapeutics with reduced time and cost to foster industry discovery. Nuritas has attracted key global opinion leaders to participate in the panel discussions to understand how companies can collaborate within industry to bring better, safer and more affordable drugs to those most in need.

Nora Khaldi, Ph.D., founder and chief scientific officer of Nuritas, commented, “Nuritas has taken a leadership position at the AI in Pharma Summit to facilitate discussion with some of the world’s largest pharmaceutical companies. We are thrilled to be key sponsors of the innovative summit comprised of global leaders committed to bringing innovative, less expensive and safer new drugs to market. With drug prices spiraling, we now have the power, using AI, to significantly reduce discovery times and costs for more affordable drugs for patients globally. We look forward to bringing Nuritas’s unique perspective to the wider AI community.”

In addition to the workshop, Dr. Khaldi will give a presentation entitled “In Silico Predictions & In Vivo Correlations: The importance of Data Quality and Integrity in Driving AI empowered Discovery” as a part of the use case plenary session.

Workshop Pannelists: Nora Khaldi, Founder and Chief Scientific Officer, Nuritas, Vanita Sood, Global Head of Drug Structure, EMD Serono, Inc., John Baldoni, Senior Vice President, Head of In Silico Drug Discovery, GSK Pharma R&D, Lina Williamson, Director, Entrepreneurship & Innovation Translational Accelerator, Brigham and Women's Hospital - Harvard University, Alan Kopin, Professor of Medicine and Director, Molecular Pharmacology Research Center, Tufts Medical Center and Agam Sheth, Director Enabling Technologies, Merck Research Laboratories, Merck & Co., Inc.

For more information:
https://www.aiinpharma.com - Full agenda at: https://www.aiinpharma.com/#agenda
To follow on social media: #AIinPharma @NuritasResearch @AIinPharma

About Nuritas
Founded in 2014, Nuritas is solving the unmet medical needs of the world with the unparalleled capability to develop preventative and curative peptide-based treatments for disease with industry leading speed and accuracy. It is successfully doing so currently in collaboration with a number of industry leading multinationals. The company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artificial intelligence (AI) platform, with in silico predictions validated by their in-house multidisciplinary team of scientists and laboratory. Nuritas engages in collaborative partnerships in the pharmaceutical and consumer goods industries to conduct peptide discovery that is faster, more accurate, and less expensive than traditional drug discovery.

Nuritas has received global recognition for the impact its innovative technology which includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, the Nutrition Capital Network Venture competition in October 2016 and support from EU Horizon 2020 in 2016 for a peptide that carries the potential to prevent pre-diabetic patients from developing diabetes.

Media Contact:
Allison Blum, Ph.D.
LifeSci Public Relations
646.627.8383

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality16.8.2019 17:17:00 CESTPress release

Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger and more active than higher-risk patients. The expanded indication approval is based on randomized clinical data from the global, prospective, multi-center Evolut Low Risk Trial, which evaluated three valve generations (CoreValve™, Evolut™ R, and Evolut™ PRO valves) in more than 1,400 patients. The data showed TAVR to have an excellent safety prof

Acacia Pharma Group plc - Issue of Equity on Exercise of Options16.8.2019 16:39:00 CESTPress release

Cambridge, UK and Indianapolis, US – 16 August 2019: Acacia Pharma Group plc (the "Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 106,997 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s [Enterprise Management Incentive Share Option Plan]. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue. Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 53,442,417 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of votin

Conditions for Riksbank Bid Procedures Sek Bonds16.8.2019 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2019-08-22 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/ -250 Settlement date 2019-08-26 Bids have to be entered by 10.00 on AUG 22, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON AUG 22, 2019 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

Correction: Prosafe SE: Publication of Information Memorandum16.8.2019 15:05:00 CESTPress release

Correction: the Information Memorandum was not attached to the previous announcement, and has now been attached. Not for release, publication or distribution, in whole or in part, in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. Reference is made to announcement of 3 June 2019 concerning the merger agreement between Prosafe SE ("Prosafe", OSE ticker PRS) and Floatel International Ltd ("Floatel"). Pursuant to section 3.5 of the Oslo Stock Exchange Continuing Obligations for listed companies, Prosafe has today published an information memorandum in respect of the merger. A copy of the information memorandum is available on www.newsweb.no and on Prosafe's website along with relevant financial reports at the following link: https://www.prosafe.com/information-memorandum/category1096.html Stavanger, 16 August 2019 Prosafe SE For further questions, please contact: Glen Ole Rødland, Chairman of Prosafe: + 47 907 41 662 Jesper K

Avance Gas Holding Ltd - Invitation to Earnings Release Audio Webcast for the Second Quarter of 201916.8.2019 14:38:00 CESTPress release

Bermuda, 16 August 2019 - Avance Gas Holding Ltd (OSE: "AVANCE"), will on Thursday 22 August 2019 release its unaudited results for the second quarter of 2019. In connection with the earnings release, an audio webcast and conference call will be held at 15:00 (CET). The webcast can be accessed at Avance Gas' website www.avancegas.com. Dial in details are +44 (0) 2071 928 000 (UK and International), +1 631 510 7495 (US) or +47 23 96 02 64 (Norway). Please quote the passcode: 3835678. Phone lines will open 10 minutes before the conference call. For further queries, please contact: Peder C. G. Simonsen CFO Tel: +47 22 00 48 15 Email: p.simonsen@avancegas.com ABOUT AVANCE GAS Avance Gas Holding Ltd operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs), operating a fleet of 14 modern VLGC. For more information about Avance Gas, please visit: www.avancegas.com This i